Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

BMC Public Health

Yan-Cheng Xu^1,17  Li-Xin Shi^1,18  Jia-Pu Ge¹  Jing Liu^1,12  Qiu-He Ji^2,20  Hao-Ming Tian^1,19  Qi-Fu Li^2,22  Zhi-Gang Zhao^2,23  Li Chen⁷  Li-Yong Yang^1,16  Da-Long Zhu⁹  Ren-Ming Hu^1,15  Yu-Zhi Yang⁵  Zhong-Yan Shan³  Jie Liu^1,10  De-Min Yu^2,24  Zhi-Guang Zhou^1,14  Da-Jin Zou^1,13  Wei-Ping Jia^1,11  Jian-Ping Weng⁴  Wen-Ying Yang^2,21  Xiao-Hui Guo⁸  Ju-Ming Lu⁶  Li-Nong Ji² 

[1] Department of Endocrinology, Xinjiang Uigur Autonomous Region People’s Hospital, Urumqi, China;Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11 Xizhimen Nandajie, Beijing 100044, China;Department of Endocrinology, First Hospital of China Medical University, Shenyang, China;Department of Endocrinology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China;Department of Endocrinology, Heilongjiang Province Hospital, Harbin, China;Department of Endocrinology, Chinese PLA General Hospital, Beijing, China;Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China;Department of Endocrinology, Peking University First Hospital, Beijing, China;Department of Endocrinology, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China;Department of Endocrinology, Shanxi Provincial People’s Hospital, Taiyuan, China;Department of Endocrinology, Shanghai Sixth People’s Hospital, Shanghai, China;Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China;Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China;Department of Endocrinology, Second Xiangya Hospital of Central South University, Changsha, China;Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China;Department of Endocrinology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China;Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Endocrinology, Affiliated Hospital of Guiyang Medical College, Guiyang, China;Department of Endocrinology, West China Hospital, Sichuan University, Chengdu, China;Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi’an, China;Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China;Department of Endocrinology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China;Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Endocrinology, Tianjin Medical University Metabolic Disease Hospital, Tianjin, China

关键词: Type 2 diabetes mellitus;    Oral antidiabetes drugs (OADs);    Insulin;    HbA1c;    GLP-1 receptor agonists;    China;   

Others  :  1162081
DOI  :  10.1186/1471-2458-13-602

 received in 2012-07-17, accepted in 2013-05-14,  发布年份 2013

【 摘 要 】

Background

The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for treatment of T2DM across multiple regions in China.

Methods

This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011.

Results

A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454 [0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin (HbA1c) levels (±SD) of 7.67% (±1.58%), 8.21% (±1.91%), and 7.80% (±1.76%), respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM.

Conclusions

Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.

【 授权许可】

   
2013 Ji et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Fu H, Shen SX, Chen ZW, Wang JJ, Ye TT, LaPorte RE, Tajima N: Shanghai, China, has the lowest confirmed incidence of childhood diabetes in the world. Diabetes Care 1994, 17:1206-1208.
• [2]Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J: Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
• [3]Zhao D, Zhao F, Li Y, Zheng Z: Projected and observed diabetes epidemics in China and beyond. Curr Cardiol Rep 2012, 14:106-111.
• [4]UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
• [5]Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192.
• [6]UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
• [7]Chinese Diabetes Society: China guideline for type 2 diabetes. Chin J Diabetes Mellitus 2010, 2(suppl 2):6-56.
• [8]American Diabetes Association: Standards of medical care in diabetes–2013. Diabetes Care 2013, 36(suppl 1):S11-S66.
• [9]So WY, Raboca J, Sobrepena L, Yoon KH, Deerochanawong C, Ho LT, Himathongkam T, Tong P, Lyubomirsky G, Ko G, Nan H, Chan J: Comprehensive risk assessments of diabetic patients from seven Asian countries: the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 2011, 3:109-118.
• [10]Editorial: China's major health challenge: control of chronic diseases. Lancet 2011, 378:457.
• [11]Zhang SL, Chen ZC, Yan L, Chen LH, Cheng H, Ji LN: Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. Chinese Med J (Engl) 2011, 124:2461-2468.
• [12]Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
• [13]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
• [14]Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC: Use of anti-diabetic drugs and glycaemic control in type 2 diabetes–The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2008, 82:346-352.
• [15]Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferrera SR, Hancu N, Ilkova H, Ramchandran A, Aschner P: Multifaceted determinants for achieving glycemic control: The international diabetes management practice study (IDMPS). Diabetes Care 2009, 32:227-233.
• [16]Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, Ramachandran A: Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab 2012, 38:128-134.
• [17]US National Institute of Diabetes and Digestive and Kidney Diseases: US National Institutes of Health. NIH publication no: Diabetes in America, 2nd edition; 95-1468. [http://diabetes.niddk.nih.gov/dm/pubs/america/contents.aspx webcite]
• [18]Bi Y, Zhu D, Cheng J, Zhu Y, Xu N, Cui S, Li W, Cheng X, Wang F, Hu Y, Shen S, Weng J: The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. Clin Ther 2010, 32:973-983.